Showing 1 - 3 results of 3 for search 'M. Simkovic', 查询时间: 0.02s Refine Results
  1. 1
    Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies

    Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies 由 P. Kralickova, J. Kuhnova, O. Soucek, P. Vodarek, P. Zak, M. Simkovic, M. Motyckova, L. Smolej, E. Mala, C. Andrys, J. Krejsek, V. Thon

    出版 2017-01-01
    获取全文
    文件
  2. 2
    P676: LOW-DOSE FCR COMPARED TO BR IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT TP53 ABERRATIONS: A REAL – WORLD RETROSPECTIVE ANALYSIS BY THE CZECH CLL STUDY GROUP.

    P676: LOW-DOSE FCR COMPARED TO BR IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT TP53 ABERRATIONS: A REAL – WORLD RETROSPECTIVE ANALYSIS BY THE CZECH CL... 由 L. Smolej, Y. Brychtová, E. Cmunt, M. Oršulová, P. Vodárek, M. Dostál, P. Turcsányi, R. Urbanová, A. Panovská, J. Zuchnická, J. Mihályová, D. Lysák, M. Brejcha, H. Móciková, K. Klásková, M. Šimkovič, M. Špaček, M. Doubek

    出版 2022-06-01
    获取全文
    文件
  3. 3
    P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP

    P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP 由 P. Ghia, A. Pluta, M. Wach, D. Lysak, M. Simkovic, I. Kriachok, A. Illes, J. de la Serna, S. Dolan, P. Campbell, G. Musuraca, A. Jacob, E. Avery, J. H. Lee, G. Usenko, M. H. Wang, T. Yu, W. Jurczak

    出版 2022-06-01
    获取全文
    文件

检索工具: